Research article
Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
- † Equal contributors
1 Department of Medicine, University of Alcalá, N-II km 33, Alcala de Henares 28871, Spain
2 Immune System Diseases and Oncology Service, University Hospital "Príncipe de Asturias", N-II km 33, Alcala de Henares 28871, Spain
3 Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester, 601 Elmwood Ave, Rochester, NY 14642, USA
Arthritis Research & Therapy 2012, 14:R175 doi:10.1186/ar3928
Published: 27 July 2012Additional files
Additional file 1:
Absolute number of circulating monocytes and of their subsets in untreated naive and MTX-treated active patients with RA and healthy controls. The absolute number (cells/μl) of circulating monocytes (panel A), CD14+highCD16- (panel B), CD14+highCD16+ (panel C) and CD14+lowCD16+ monocytes (panel D) of untreated naive and MTX-treated active patients with RA and of healthy controls, are shown as the mean ± SEM. * Significant difference between patients with RA and healthy controls.
Format: EPS Size: 2.1MB Download file
Additional file 2:
Absolute number of circulating monocytes and of their subsets in untreated naive and MTX-treated active patients with RA and healthy controls. Panel A represents flow cytometry analysis of circulating monocytes from a representative patient. The percentage of circulating monocytes, CD14+highCD16- (panel B), CD14+highCD16+ (panel C) and CD14+lowCD16+ monocytes (panel D) of untreated naive and MTX-treated active patients with RA and of healthy controls, are shown as the mean ± SEM. * Significant difference between patients with RA and healthy controls.
Format: EPS Size: 2.1MB Download file
